Communiqués Santen Pharmaceutical Co., Ltd. Börse Stuttgart

Actions

SZD

JP3336000009

Produits pharmaceutiques

Marché Fermé - Börse Stuttgart Autres places de cotation 21:55:41 31/07/2026			Varia. 5j.	Varia. 1 janv.
10,10 ^EUR	-4,72%		-2,88%	+16,09%

27/07	Glaukos achève le recrutement pour l'essai clinique du Preserflo MicroShunt	MT
13/07	KYORIN Pharmaceutical et Santen Pharmaceutical concluent un accord de co-commercialisation pour la crème Alesion 0,5 %, traitement de la conjonctivite allergique	CI

Communiqués

13/07	Santen Pharmaceutical : and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%	PU
26/06	Santen Pharmaceutical : Obtains Marketing Approval in the Philippines for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia — First Approval in ’s Asia Business Region	PU
19/06	Santen Pharmaceutical : Obtains Manufacturing and Marketing Approval in Japan for Rhopressa® Ophthalmic Solution 0.02%, a Treatment for Glaucoma and Ocular Hypertension	PU
17/04	Santen Pharmaceutical : China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland	PU
19/03	Santen Pharmaceutical : Notice of Board of Director and Corporate Auditor Nominations	PU
09/01	Santen Pharmaceutical : Launch of Aflibercept kit for IVT inj. 40 mg/mL Bayer	PU
23/12	Santen Pharmaceutical : Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults	PU
22/12	Santen Pharmaceutical : Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis	PU
05/12	Santen Pharmaceutical : Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List	PU
03/12	Santen Pharmaceutical : and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases	PU
20/11	Santen Pharmaceutical : On December 1, Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”	PU
06/11	Santen Pharmaceutical : Announces Cancellation of Treasury Shares	PU
06/11	Santen Pharmaceutical : Announces Completion of Share Buyback	PU
06/11	Santen Pharmaceutical : Summary of Consolidated Financial Results for the Six Months Ended September 30, 2025 (IFRS)	PU
04/11	Santen Pharmaceutical : Announces Status of Share Buyback	PU
23/10/25	Santen Pharmaceutical : Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension	PU
20/10/25	Santen Pharmaceutical : Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea	PU
16/10/25	Santen Pharmaceutical : Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”	PU
01/10/25	Santen Pharmaceutical : Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan	PU
01/10/25	Santen Pharmaceutical : Announces Status of Share Buyback	PU
30/09/25	Santen Pharmaceutical : and RemeGen Announce Biologic License Application (BLA) Acceptance for RC28-E Intravitreal Injection in Diabetic Macular Edema in China	PU
25/09/25	Santen Pharmaceutical : Publishes its Annual Integrated Report “ Report 2025”	PU
04/09/25	Santen Pharmaceutical : Helps Families Learn about Eye Health through “Learning Festival Summer 2025” Interactive Workshop	PU
03/09/25	Santen Pharmaceutical : Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan	PU
01/09/25	Santen Pharmaceutical : Launches TAPCOM® in China for Patients with Open-Angle Glaucoma or Ocular Hypertension	PU